NorthStrive Biosciences Announces The Filing of Two U.S. Patent Applications Targeting Microgravity-Induced Muscle Loss During Long-Duration Spaceflight

NorthStrive Biosciences, a wholly owned subsidiary of PMGC Holdings (ELAB), filed two U.S. patent applications for its preclinical assets EL-22 and EL-32, targeting microgravity-induced muscle loss during spaceflight. The filings aim to broaden the IP portfolio for myostatin and activin A inhibition, extending beyond terrestrial weight loss applications to the emerging space health market.

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.